PSI Launches SYNETIC™ to Speed up Site ID, Startup, and Enrollment in Pivotal Studies

Zug, Switzerland, 29th January 2026 / Sciad Communications / PSI CRO, a Swiss-based global full-service contract research organization (CRO), today announced the launch of SYNETIC™, a next-generation AI-powered semantic knowledge platform that empowers sponsors to identify optimal trial sites, minimize startup delays, and predict and eliminate non-enrolling sites.

Underperforming sites are a persistent industry challenge, directly impacting trial timelines and budgets: 37% of sites enroll poorly, and 11% never enroll a single patient.¹ SYNETIC™’s foundation of over 500,000 unique institutions and 3 million study sites across 62 countries equips PSI’s sponsors and operational teams with real-time, data driven insights into site capabilities, operational efficiency, and patient recruitment performance, ensuring that even the most complex global trials stay on track and meet aggressive timelines.

SYNETIC™ is a new addition to PSI’s award-winning INTELIA™ Clinical Trial Intelligence

Platform, which unites operational excellence, predictive analytics, and AI-enabled decision support to optimize every phase of trial planning and execution.

What SYNETIC™ delivers for the industry and PSI sponsors:

• Instant Site Intelligence: Rapid generation of comprehensive site lists with in-depth data on institutional capabilities, workload, and prior performance
• AI-Driven Site Scoring: Automated algorithmic ranking of sites by protocol fit based on enrollment history, therapeutic expertise, and geographic performance
• Agentic AI and Semantic Search: More accurate study matching using sophisticated agentic AI, leveraging Natural Language Processing (NLP) to query SYNETIC™’s data set using semantic search and LLM-augmented reasoning
• Data-driven Site Matching: Enhanced feasibility assessments powered by advanced AI models for targeted outreach to sites most likely to successfully recruit
• Interactive Knowledge Graphs: Predictive analytics based on complex relationships across millions of data points, connecting institutions, investigators, and trial performance
• Real-Time Insights: Evidence-based insights in real time through a next-gen semantic data architecture powered by PSI’s enterprise ontology

“INTELIA™ enables pharma and biotech sponsors to see what works and what doesn’t for their trial before it begins,” said Kirill Soldatov, Head of Process Improvement at PSI. “SYNETIC™ takes this to the next level, by eliminating blind spots in site selection and patient enrollment. It’s not just a platform – it’s a core enabler of PSI’s promise to sponsors: that teams will deliver, on time, every time, even under the most demanding conditions and in any geography.”

To learn more about how SYNETIC™ helps clinical teams reduce clinical trial startup timelines and accelerate patient enrollment worldwide, contact our team.